ClinicalTrials.gg
CompletedNCT04052360Updated Sep 22, 2025

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

A Phase 1 interventional study of Cenerimod and Matching Placebo in Healthy Volunteers, sponsored by Viatris Innovation GmbH. Completed at 1 site in United States. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2019, 7 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

This study is for research purposes only and is not intended to treat any medical condition. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of cenerimod following a single dose in healthy Japanese and Caucasian participants. Pharmacokinetics is the study of the absorption and breakdown of the study drug in the body. Pharmacodynamics is the study of the effect of the study drug on the body. There will be 2 groups in the study. 10 Japanese participants in one group and 10 Caucasian participants in the other group.

The duration of participation in this study is approximately 75 days from screening to the end of study visit. A screening visit is required within 21 days prior to the start of the study to determine whether the volunteer qualifies and is willing to participate in this research study. This study requires in-patient stay in the research clinic of 4 days (3 nights) followed by outpatient visits and an end of study visit 3 to 5 days after the day 49 outpatient visit.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Viatris Innovation GmbH is the lead sponsor of 24 studies on the registry; 3 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in a language understandable to the subject prior to any study-mandated procedure.
  • of 18.0 to 28.0 kg/m\^2 (inclusive) at the screening.
  • Ability to communicate well with the investigator, in a language understandable to the subject, and to understand and comply with the requirements of the study.
  • No findings on the physical examination at screening.
  • Systolic blood pressure 100 to 145 mmHg, diastolic blood pressure 50 to 90 mmHg, and pulse rate 55 to 90 bpm (inclusive), measured on the same arm, after 5 min in the supine position at screening and on admission.
  • 12-lead without clinically relevant abnormalities, measured after 5 min in the supine position at Screening and on admission.
  • No clinically relevant findings in clinical laboratory tests (hematology, clinical chemistry, and urinalysis) at screening and on admission.
  • Negative results from urine drug screen and breath alcohol tests at screening and on admission.
  • Subjects must be of Caucasian or Japanese ethnicity.

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to cenerimod.
  • Known or allergy to natural rubber latex, to or any of the .
  • History of major medical or surgical disorders which are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed).
  • Acute, ongoing, recurrent, or chronic systemic disease able to interfere with the evaluation.
  • history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.
  • Lymphopenia (less than 1.0 x 10\^9 cells/L) at screening and on admission.
  • Familial history of sick-sinus syndrome.
  • Any cardiac condition or illness (including (ECG) abnormalities with a potential to increase the cardiac risk.
  • Familial history of sick-sinus syndrome.
  • Any recent treatment.
  • History or clinical evidence of alcoholism or drug abuse.
  • Excessive caffeine consumption, defined as 800 mg or more per day at screening.
  • Nicotine consumption within 3 months prior to screening and inability to refrain from nicotine consumption.
  • Previous treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals).
  • Viral, fungal, bacterial or protozoal infection and / or serology.
  • Legal incapacity or limited legal capacity at screening.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Cenerimod / ACT-334441

    Drug: Cenerimod

  • Placebo comparator
    Matching Placebo

    Drug: Matching Placebo

Interventions

  • A single oral dose of 4 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.

    Also known as: ACT-334441

  • DrugMatching Placebo

    A single oral dose of matching placebo will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.

06

What researchers measure

Primary outcomes

  1. The area under the plasma concentration-time curve (AUC) for cenerimod

    The plasma PK parameter of cenerimod will be derived by non-compartmental analysis of plasma concentration-time profiles.

    Time frame: From Day 1 to Day 49

Secondary outcomes

  1. Maximum plasma concentration (Cmax) for cenerimod

    The plasma PK parameter of cenerimod will be derived by non-compartmental analysis of plasma concentration-time profiles.

    Time frame: From Day 1 to Day 49

  2. Time to reach the maximum plasma concentration (tmax) for cenerimod

    The plasma PK parameter of cenerimod will be derived by non-compartmental analysis of plasma concentration-time profiles.

    Time frame: From Day 1 to Day 49

  3. Terminal half-life [t(1/2)] of cenerimod

    The plasma PK parameter of cenerimod will be derived by non-compartmental analysis of plasma concentration-time profiles.

    Time frame: From Day 1 to Day 49

  4. Lymphocyte count

    The lymphocyte count will be used as a measure of immunomodulation (a change in the body's immune system).

    Time frame: Day 1, Day 3, Day 6, Day 9, Day 12, Day 15, Day 18, Day 21, Day 28, Day 35, Day 42 and Day 49

07

Study locations

1 site
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Oct 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2019
First posted
Aug 9, 2019
StartActual
Aug 7, 2019
Primary completionActual
Oct 29, 2019
CompletionActual
Nov 2, 2019
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04052360
Responsible party
Sponsor
First posted
Aug 9, 2019
Start date
Aug 7, 2019
Primary completion
Oct 29, 2019
Completion
Nov 2, 2019
Last update
Sep 22, 2025

Study contacts

Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenerimod

Start the discussion